The Importance of Cardiac Assessment in the Era of Biologic Therapies for Psoriasis

2021 ◽  
pp. 419-430
Author(s):  
Carmen Salavastru ◽  
Dedee F. Murrell ◽  
James Otton
Keyword(s):  
Biologic Therapies ◽  
Cardiac Assessment

Applying personalized medicine to adult severe asthma

2021 ◽  
Vol 42 (1) ◽  
pp. e8-e16 ◽  
Author(s):  
Angelica Tiotiu
Keyword(s):  
Personalized Medicine ◽  
Severe Asthma ◽  
Negative Impact ◽  
Target Therapy ◽  
Asthma Management ◽  
Future Research ◽  
Biologic Therapies ◽  
Eosinophilic Asthma ◽  
Definition Of ◽  
Structured Approach

Background: Severe asthma is a heterogeneous disease that consists of various phenotypes driven by different pathways. Associated with significant morbidity, an important negative impact on the quality of life of patients, and increased health care costs, severe asthma represents a challenge for the clinician. With the introduction of various antibodies that target type 2 inflammation (T2) pathways, severe asthma therapy is gradually moving to a personalized medicine approach. Objective: The purpose of this review was to emphasize the important role of personalized medicine in adult severe asthma management. Methods: An extensive research was conducted in medical literature data bases by applying terms such as “severe asthma” associated with “structured approach,” “comorbidities,” “biomarkers,” “phenotypes/endotypes,” and “biologic therapies.” Results: The management of severe asthma starts with a structured approach to confirm the diagnosis, assess the adherence to medications and identify confounding factors and comorbidities. The definition of phenotypes or endotypes (phenotypes defined by mechanisms and identified through biomarkers) is an important step toward the use of personalized medicine in asthma. Severe allergic and nonallergic eosinophilic asthma are two defined T2 phenotypes for which there are efficacious targeted biologic therapies currently available. Non-T2 phenotype remains to be characterized, and less efficient target therapy exists. Conclusion: Despite important progress in applying personalized medicine to severe asthma, especially in T2 inflammatory phenotypes, future research is needed to find valid biomarkers predictive for the response to available biologic therapies to develop more effective therapies in non-T2 phenotype.

The Use of Biologic Therapies in the Treatment of Rheumatoid Arthritis

2014 ◽  
Vol 15 (6) ◽  
pp. 542-548 ◽  
Author(s):  
Dashan Wang ◽  
Yan Li ◽  
Yuan Liu ◽  
Guixiu Shi
Keyword(s):  
Rheumatoid Arthritis ◽  
Biologic Therapies

Biologic therapies in systemic lupus erythematosus

2015 ◽  
Vol 18 (2) ◽  
pp. 146-153 ◽  
Author(s):  
Christine B. Bernal ◽  
Leonid D. Zamora ◽  
Sandra V. Navarra
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Biologic Therapies ◽  
Systemic Lupus

scholarly journals COVID-19 prevalence and outcomes in patients receiving biologic therapies at an infusion center in New York City

2021 ◽  
pp. 108803
Author(s):  
Kaoru Harada ◽  
Hsi-en Ho ◽  
Charlotte Cunningham-Rundles
Keyword(s):  
New York ◽  
New York City ◽  
York City ◽  
Biologic Therapies

scholarly journals Vasculitis: From Target Molecules to Novel Therapeutic Approaches

Biomedicines ◽  
2021 ◽  
Vol 9 (7) ◽  
pp. 757
Author(s):  
Sang-Wan Chung
Keyword(s):  
Systemic Vasculitis ◽  
Alkylating Agents ◽  
Large Vessel Vasculitis ◽  
Large Vessel ◽  
Biologic Therapies ◽  
Therapeutic Approaches ◽  
Novel Treatments ◽  
Treatment Regimens ◽  
Immune Mediated ◽  
Target Molecules

Systemic vasculitis is a group of diverse diseases characterized by immune-mediated inflammation of blood vessels. Current treatments for vasculitis, such as glucocorticoids and alkylating agents, are associated with significant side effects. In addition, the management of both small and large vessel vasculitis is challenging due to a lack of robust markers of disease activity. Recent research has advanced our understanding of the pathogenesis of both small and large vessel vasculitis, and this has led to the development of novel biologic therapies capable of targeting key cytokine and cellular effectors of the inflammatory cascade. It is anticipated that these novel treatments will lead to more effective and less toxic treatment regimens for patients with systemic vasculitis.

A Brief History of Psoriasis Management in Canada

2020 ◽  
Vol 24 (3) ◽  
pp. 273-277
Author(s):  
Khalad Maliyar ◽  
Patrick Fleming ◽  
Boluwaji Ogunyemi ◽  
Charles Lynde
Keyword(s):  
20Th Century ◽  
Coal Tar ◽  
Historical Review ◽  
Chronic Inflammatory Disease ◽  
Biologic Therapies ◽  
First Line ◽  
Revolutionary Change ◽  
Clinical Presentations ◽  
History Of ◽  
The 19Th Century

Psoriasis is a chronic, inflammatory disease with a varying degree of clinical presentations. Managing psoriasis has always been arduous due to its chronicity and its propensity to relapse. Prior to the development of targeted biologic therapies, there were few effective treatments for psoriasis. Ancient psoriasis therapies included pinetar, plant extracts, psychotherapy, arsenic, and ammoniated mercury. In the 19th century, chrysarobin was developed. Then, in the early half of the 20th century, anthralin and coal tar were in widespread use. In the latter half of the 20th century, treatments were limited to topical first-line therapies, systemic drugs, and phototherapy. However, as the treatment of psoriasis has undergone a revolutionary change with the development of novel biologic therapies, patients with moderate to severe psoriasis have been able to avail therapies with high efficacy and durability along with an acceptable safety profile. This article is a brief historical review of the management of psoriasis prior to the inception of biologics and with the development of novel biologic therapies.

Sign in / Sign up

Export Citation Format

Share Document